Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

MS is classified according to its progression over time. Secondary progressive MS (SPMS) typically develops some time after a diagnosis of relapsing-remitting MS (RRMS). RRMS features clearly ...

More than one million people in the United States live with Multiple Sclerosis (MS), a chronic neurological disease that ...

Tiziana Life Sciences has announced promising results from an open-label study of its investigational multiple sclerosis (MS) ...

The article is titled “Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS ...

HERCULES evaluated 1,131 non-relapsing secondary progressive MS patients with a median baseline EDSS of 6.0 who were randomized to tolebrutinib or placebo. In HERCULES, tolebrutinib slowed ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Progressive resistance training didn't lower cardiovascular risk in people with secondary progressive multiple sclerosis (SPMS), per a study.

To provide the right treatment for MS, it is important to know when the disease changes from relapsing-remitting to secondary ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

To provide the right treatment for MS, it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently recognized on average three ...